盐皮质激素受体阻断、高血压与心力衰竭 - Suppr

Suppr

超能文献

Mineralocorticoid-receptor blockade, hypertension and heart failure.

作者信息

Funder John W

机构信息

Monash University, Australia.

出版信息

Nat Clin Pract Endocrinol Metab. 2005 Nov;1(1):4-5. doi: 10.1038/ncpendmet0016.

DOI:10.1038/ncpendmet0016

PMID:16929357

Abstract

摘要

相似文献

Mineralocorticoid-receptor blockade, hypertension and heart failure.

Nat Clin Pract Endocrinol Metab. 2005 Nov;1(1):4-5. doi: 10.1038/ncpendmet0016.

Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.

Heart Dis. 2003 Sep-Oct;5(5):354-63. doi: 10.1097/01.hdx.0000089783.30450.cb.

Aldosterone antagonists in heart failure.

J Cardiovasc Pharmacol Ther. 2011 Jun;16(2):150-9. doi: 10.1177/1074248410387606. Epub 2010 Dec 15.

Eplerenone and chronic heart failure. No comparison with spironolactone.

Prescrire Int. 2013 Jun;22(139):148-9.

Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.

Nat Clin Pract Cardiovasc Med. 2007 Jul;4(7):368-78. doi: 10.1038/ncpcardio0914.

Aldosterone target organ protection by eplerenone.

Mol Cell Endocrinol. 2004 Mar 31;217(1-2):229-38. doi: 10.1016/j.mce.2003.10.047.

Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure.

Cardiovasc Revasc Med. 2006 Oct-Dec;7(4):234-6. doi: 10.1016/j.carrev.2006.07.002.

The role of aldosterone receptor blockade in the management of cardiovascular disease.

Curr Opin Investig Drugs. 2002 Oct;3(10):1468-73.

[Selective aldosterone blocker for hypertension and heart failure. Better tolerance than previous drugs].

MMW Fortschr Med. 2002 Sep 26;144(39):50.

Eplerenone (GD Searle & Co).

Curr Opin Investig Drugs. 2001 Apr;2(4):521-4.

引用本文的文献

Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.

Curr Hypertens Rep. 2020 Feb 29;22(3):21. doi: 10.1007/s11906-020-1023-y.

New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure.

J Nephrol. 2020 Feb;33(1):37-48. doi: 10.1007/s40620-019-00600-7. Epub 2019 Apr 15.

Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

J Cardiovasc Pharmacol. 2016 Jan;67(1):26-38. doi: 10.1097/FJC.0000000000000329.

Interfering with mineralocorticoid receptor activation: the past, present, and future.

F1000Prime Rep. 2014 Aug 1;6:61. doi: 10.12703/P6-61. eCollection 2014.

Is there a new dawn for selective mineralocorticoid receptor antagonism?

Curr Opin Nephrol Hypertens. 2014 Sep;23(5):456-61. doi: 10.1097/MNH.0000000000000051.

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.

J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22.

Mineralocorticoid antagonism and cardiac hypertrophy.

Curr Hypertens Rep. 2008 Jun;10(3):216-21. doi: 10.1007/s11906-008-0041-y.

Nuclear receptors: decoding metabolic disease.

FEBS Lett. 2008 Jan 9;582(1):2-9. doi: 10.1016/j.febslet.2007.11.016. Epub 2007 Nov 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Mineralocorticoid-receptor blockade, hypertension and heart failure.

Nat Clin Pract Endocrinol Metab. 2005 Nov;1(1):4-5. doi: 10.1038/ncpendmet0016.

Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.

Heart Dis. 2003 Sep-Oct;5(5):354-63. doi: 10.1097/01.hdx.0000089783.30450.cb.

Aldosterone antagonists in heart failure.

J Cardiovasc Pharmacol Ther. 2011 Jun;16(2):150-9. doi: 10.1177/1074248410387606. Epub 2010 Dec 15.

Eplerenone and chronic heart failure. No comparison with spironolactone.

Prescrire Int. 2013 Jun;22(139):148-9.

Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.

Nat Clin Pract Cardiovasc Med. 2007 Jul;4(7):368-78. doi: 10.1038/ncpcardio0914.

Aldosterone target organ protection by eplerenone.

Mol Cell Endocrinol. 2004 Mar 31;217(1-2):229-38. doi: 10.1016/j.mce.2003.10.047.

Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure.

Cardiovasc Revasc Med. 2006 Oct-Dec;7(4):234-6. doi: 10.1016/j.carrev.2006.07.002.

The role of aldosterone receptor blockade in the management of cardiovascular disease.

Curr Opin Investig Drugs. 2002 Oct;3(10):1468-73.

[Selective aldosterone blocker for hypertension and heart failure. Better tolerance than previous drugs].

MMW Fortschr Med. 2002 Sep 26;144(39):50.

Eplerenone (GD Searle & Co).

Curr Opin Investig Drugs. 2001 Apr;2(4):521-4.

引用本文的文献

Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.

Curr Hypertens Rep. 2020 Feb 29;22(3):21. doi: 10.1007/s11906-020-1023-y.

New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure.

J Nephrol. 2020 Feb;33(1):37-48. doi: 10.1007/s40620-019-00600-7. Epub 2019 Apr 15.

Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

J Cardiovasc Pharmacol. 2016 Jan;67(1):26-38. doi: 10.1097/FJC.0000000000000329.

Interfering with mineralocorticoid receptor activation: the past, present, and future.

F1000Prime Rep. 2014 Aug 1;6:61. doi: 10.12703/P6-61. eCollection 2014.

Is there a new dawn for selective mineralocorticoid receptor antagonism?

Curr Opin Nephrol Hypertens. 2014 Sep;23(5):456-61. doi: 10.1097/MNH.0000000000000051.

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.

J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22.

Mineralocorticoid antagonism and cardiac hypertrophy.

Curr Hypertens Rep. 2008 Jun;10(3):216-21. doi: 10.1007/s11906-008-0041-y.

Nuclear receptors: decoding metabolic disease.

FEBS Lett. 2008 Jan 9;582(1):2-9. doi: 10.1016/j.febslet.2007.11.016. Epub 2007 Nov 20.